I will certainly be listening in for the investor call, hopefully to hear some good news. One never knows what's going on with a public company until the releases, but we'll see. If hospitals continue to add to formulary, and there is ANY indication of acceptance as first-line treatment by GI, I predict strong upside as the main argument put forth on this board will have been put out to pasture. However, if there is no indication of physician acceptance to treat seniors and others who represent a population susceptible to reinfection or multiple recurrences initially with Dificid, I will become concerned. Right now, I am confident Monday's call will be positive re: sales, education and acceptance; but, just my opinion. Good luck to all.